The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York City, USA.
BMC Public Health. 2013 Jan 19;13:53. doi: 10.1186/1471-2458-13-53.
Persons who inject drugs (PWID) are at an elevated risk for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. In many high-income countries, needle and syringe exchange programs (NSP) have been associated with reductions in blood-borne infections. However, we do not have a good understanding of the effectiveness of NSP in low/middle-income and transitional-economy countries.
A systematic literature review based on PRISMA guidelines was utilized to collect primary study data on coverage of NSP programs and changes in HIV and HCV infection over time among PWID in low-and middle-income and transitional countries (LMICs). Included studies reported laboratory measures of either HIV or HCV and at least 50% coverage of the local injecting population (through direct use or through secondary exchange). We also included national reports on newly reported HIV cases for countries that had national level data for PWID in conjunction with NSP scale-up and implementation.
Studies of 11 NSPs with high-coverage from Bangladesh, Brazil, China, Estonia, Iran, Lithuania, Taiwan, Thailand and Vietnam were included in the review. In five studies HIV prevalence decreased (range -3% to -15%) and in three studies HCV prevalence decreased (range -4.2% to -10.2%). In two studies HIV prevalence increased (range +5.6% to +14.8%). HCV incidence remained stable in one study. Of the four national reports of newly reported HIV cases, three reported decreases during NSP expansion, ranging from -30% to -93.3%, while one national report documented an increase in cases (+37.6%). Estimated incidence among new injectors decreased in three studies, with reductions ranging from -11/100 person years at risk to -16/100 person years at risk.
While not fully consistent, the data generally support the effectiveness of NSP in reducing HIV and HCV infection in low/middle-income and transitional-economy countries. If high coverage is achieved, NSP appear to be as effective in LMICs as in high-income countries. Additional monitoring and evaluation research is needed for NSPs where reductions in HIV/HCV infection among PWID are not occurring in order to identify and correct contributing problems.
注射毒品者(PWID)感染人类免疫缺陷病毒(HIV)和丙型肝炎病毒(HCV)的风险较高。在许多高收入国家,针具交换计划(NSP)与血液传播感染的减少有关。然而,我们对中低收入和转型经济体国家(LMIC)中 NSP 的有效性没有很好的了解。
根据 PRISMA 指南进行了系统文献综述,以收集关于低/中收入和过渡经济体国家(LMIC)中 NSP 计划的覆盖范围以及 PWID 中 HIV 和 HCV 感染随时间变化的主要研究数据。纳入的研究报告了 HIV 或 HCV 的实验室测量值,并且至少有 50%的当地注射人群(通过直接使用或通过二次交换)。我们还包括了在国家一级为 PWID 提供 NSP 扩大和实施数据的国家新报告的 HIV 病例报告。
该综述纳入了来自孟加拉国、巴西、中国、爱沙尼亚、伊朗、立陶宛、中国台湾、泰国和越南的 11 项高覆盖 NSP 研究。在五项研究中,HIV 流行率下降(范围为-3%至-15%),在三项研究中 HCV 流行率下降(范围为-4.2%至-10.2%)。在两项研究中,HIV 流行率增加(范围为+5.6%至+14.8%)。一项研究中 HCV 发病率保持稳定。在四项新报告的 HIV 病例报告中,有三项报告在 NSP 扩大期间有所减少,范围从-30%至-93.3%,而一项国家报告记录病例增加(+37.6%)。在三项研究中,新注射者的估计发病率下降,从每 100 人年风险 11 例减少到每 100 人年风险 16 例。
尽管不完全一致,但这些数据总体上支持 NSP 在减少低/中收入和转型经济体国家的 HIV 和 HCV 感染方面的有效性。如果实现高覆盖率,NSP 在 LMIC 中的有效性与高收入国家相当。需要对 HIV/HCV 感染在 PWID 中没有减少的 NSP 进行更多的监测和评估研究,以确定和纠正促成问题的因素。